에 대한 최신 뉴스 MetLife (NYSE:MET) 주식

MetLife

MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.

MetLife Inc

Metronome

Meta Platforms, Inc. - Class A Common Stock

Meta Platforms Inc

Metadium

MetagamZ

MetaPets

MetaverseX

Ramaco Resources, Inc. - Class A Common Stock

Ramaco Resources Inc

Ramaco Resources, Inc. - Class B Common Stock

Ramaco Resources, Inc. - 9.00% Senior Notes due 2026

Ramaco Resources, Inc. - 8.375% Senior Notes due 2029

Direxion Daily META Bear 1X Shares

Metis - United States Dollar

METEORIC RESORCES NL by Meteoric Resorces NL

Meteoric Resources NL

Direxion Daily META Bull 2X Shares

Roundhill Ball Metaverse ETF

ME THERAPEUTICS HLDGS by ME THERAPEUTICS HLDGS INC.

ME Therapeutics Holding Inc

MetLife, Inc. Preferred Series A Floating Rate

MetLife, Inc. Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F

<p><strong>MetLife's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has fallen 3.54% since its last report. The company recently reported that it has <strong>6.28 million shares sold short</strong>, which is 1.09% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.02 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738069220_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for MetLife has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.30%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Peering Into MetLife's Recent Short Interest

<p>MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.57, a high estimate of $99.00, and a low estimate of $88.00. Observing a 2.26% increase, the current average has risen from the previous average price target of $91.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1737633652_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of MetLife by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MetLife. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MetLife compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of MetLife's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MetLife analyst ratings.</strong></a></p>
<h2>About MetLife</h2>
<p>MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.</p>
<h3>Unraveling the Financial Story of MetLife</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>16.6%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> MetLife's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.98%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MetLife's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.39%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.18%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.61</strong>, MetLife faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

The Analyst Verdict: MetLife In The Eyes Of 7 Experts

<p>BMO Capital  analyst Jack Matten   initiates coverage on MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Market Perform rating and announces Price Target of $97.</p>


News

Price Target

Initiation

BMO Capital Initiates Coverage On MetLife with Market Perform Rating, Announces Price Target of $97

UPDATE: MetLife Responds To Report On Cyberattack, Says "We are aware of a cyberattack impacting Ecuador-based Fondo Genesis. As Fondo Genesis operates separately from MetLife's enterprise systems, this incident has not impacted any other parts of the MetLife business. Fondo Genesis is a financial services company operating only in Ecuador that is owned by Chilean pension manager ProVida, a subsidiary of MetLife."

MetLife Responds To Report On Cyberattack, Says "We are aware of a cyberattack impacting Ecuador-based Fondo Genesis. As Fondo Genesis operates separately from MetLife's enterprise systems, this incident has not impacted any other parts of the MetLife business. Fondo Genesis is a financial services company operating only in Ecuador that is owned by Chilean pension manager ProVida, a subsidiary of MetLife."

<p>Wells Fargo  analyst Elyse Greenspan   maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and lowers the price target from $93 to $92.</p>


Wells Fargo Maintains Overweight on MetLife, Lowers Price Target to $92

WIIM

CINF

ERIE

HRTG

Shares of insurance stocks are trading lower amid California wildfires.

MetLife Investment Management To Acquire Three Investment Teams And Assets Managed By Mesirow; Terms Subject To Customary Approvals And Consents

<p>JP Morgan  analyst Jimmy Bhullar   maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $86 to $88.</p>


JP Morgan Maintains Overweight on MetLife, Raises Price Target to $88

<p>Barclays  analyst Alex Scott   maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $90 to $96.</p>


Barclays Maintains Overweight on MetLife, Raises Price Target to $96

<p><a href="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true">https://www.bloomberg.com/news/articles/2024-12-23/metlife-is-said-to-near-deal-to-buy-hk-tycoon-li-s-pinebridge?embedded-checkout=true</a></p>


MetLife Nearing $1.4B Deal To Acquire PineBridge Excluding China Assets; Announcement Expected Monday, Valuing $100B AUM Outside China At $1.3B-$1.4B

<p><strong>MetLife's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) short percent of float has risen 24.14% since its last report. The company recently reported that it has <strong>6.20 million shares sold short</strong>, which is 1.08% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.18 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>MetLife Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734719411_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for MetLife has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing MetLife's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, MetLife's peer group average for short interest as a percentage of float is 2.22%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


MetLife shares are trading higher after the company announced its New Frontier growth strategy and long-term financial commitments.

<p>At the Investor Day, MetLife senior executives and other senior leaders will introduce the company's powerful five-year growth strategy, New Frontier, that is designed to support consistent delivery of:</p>
<ul>
<li>Double-digit adjusted earnings per share growth;</li>
<li>15-17% adjusted return on equity;</li>
<li>A 100-basis-point reduction in direct expense ratio target;3 and</li>
<li>Free cash flow of $25 billion.</li>
</ul>


Guidance

MetLife Outlines Long-term Financial Commitments Including Double-Digit Adjusted EPS Growth And 15-17% Adjusted Return On Equity

MetLife And General Atlantic Announce Formation Of Bermuda-Based Chariot Re With Over $1B Initial Equity Investment; Launch Expected In H1 2025; MetLife To Reinsure $10B Liabilities And Partner On Strategic Reinsurance And Asset Management Services

<p>In the preceding three months, 8 analysts have released ratings for MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $93.62, a high estimate of $99.00, and a low estimate of $90.00. Observing a 4.02% increase, the current average has risen from the previous average price target of $90.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732734080_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of MetLife among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MetLife. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of MetLife compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of MetLife's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of MetLife's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MetLife analyst ratings.</strong></a></p>
<h2>All You Need to Know About MetLife</h2>
<p>MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.</p>
<h3>Understanding the Numbers: MetLife's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>16.6%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>6.98%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MetLife's ROE excels beyond industry benchmarks, reaching <strong>4.39%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MetLife's ROA excels beyond industry benchmarks, reaching <strong>0.18%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.61</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring MetLife Through Analyst Insights

<p>TD Cowen  analyst Daniel Bergman   maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Buy and raises the price target from $97 to $99.</p>


TD Cowen Maintains Buy on MetLife, Raises Price Target to $99

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $91.22, a high estimate of $97.00, and a low estimate of $85.00. This current average reflects an increase of 4.0% from the previous average price target of $87.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730826084_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of MetLife by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Daniel Bergman</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to MetLife. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of MetLife compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for MetLife's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of MetLife's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MET/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MetLife analyst ratings.</strong></a></p>
<h2>Delving into MetLife's Background</h2>
<p>MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.</p>
<h3>MetLife's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> MetLife's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>16.6%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>6.98%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MetLife's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.39%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MetLife's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.18%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.61</strong>, MetLife adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 9 Analyst Recommendations For MetLife

<p>Wells Fargo  analyst Elyse Greenspan   maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $92 to $93.</p>


Wells Fargo Maintains Overweight on MetLife, Raises Price Target to $93

<p>Looking into the current session, <strong>MetLife Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>)</strong> shares are trading at $77.10, after a <strong>7.31%</strong> drop. Over the past month, the stock decreased by <strong>6.52%</strong>, but over the past year, it actually increased by <strong>30.00%</strong>. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1730483106_0.png" alt="Past Year Chart" /></p>

<h3>Comparing MetLife P/E Against Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>Compared to the aggregate P/E ratio of <strong>19.3</strong> in the Insurance industry, MetLife Inc. has a higher P/E ratio of <strong>22.6</strong>. Shareholders might be inclined to think that MetLife Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1730483106_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

Markets

Price Over Earnings Overview: MetLife

MetLife to acquire three investment teams, $6B of assets from Mesirow

Aflac's Shares Are Overvalued

Jefferies analyst Suneet Kamath maintained a Buy rating on Metlife (MET – Research Report) yesterday and set a price target of $104.00. The company...

Jefferies Keeps Their Buy Rating on Metlife (MET)

An announcement from Metlife ( ($MET) ) is now available. MetLife, Inc. announced that Executive Vice President and Chief Accounting Officer Tamara...

MetLife Announces Resignation of Chief Accounting Officer

In a report released today, Elyse Greenspan from Wells Fargo maintained a Buy rating on Metlife (MET – Research Report), with a price target of $92...

Wells Fargo Remains a Buy on Metlife (MET)

As of Jan. 7, 2025, UnitedHealth Group is the country's most valuable insurance company, with a market cap of $473 billion.

Visualizing America's $1.7 Trillion Insurance Industry

Dodge & Cox Stock Fund Q4 2024 Shareholder Letter

BMO Capital initiated coverage of MetLife (MET) with a Market Perform rating and $97 price target MetLife has executed on a business mix transforma...

MetLife initiated with a Market Perform at BMO Capital

Metlife (MET) has received a new Hold rating, initiated by BMO Capital analyst, Jack Matten. Jack Matten has given his Hold rating due to a combina...

Metlife's Transformation and Achievable Financial Targets Justify Hold Rating Amid Earnings Volatility

Brighthouse Financial (BHF), which was spun out of MetLife (MET) in 2017, is working with bankers at Goldman Sachs (GS) and Wells Fargo (WFC) to bo...

Comments

MetLife

뉴스

에 대한 최신 뉴스 MetLife (NYSE:MET) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌